Status:
COMPLETED
Validation of the Percentage of Alveolar Fibrocyte as Biomarker During ARDS
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Acute Respiratory Distress Syndrome (ARDS)
Mechanical Ventilation
Eligibility:
All Genders
18+ years
Brief Summary
Fibrocyte is a monocyte sub-population involved in fibroproliferation/repair processes and associated with outcome in different diseases. In previous study, we have demonstrated the presence of alveol...
Detailed Description
Background: The acute respiratory distress syndrome (ARDS) remains common (15% of ventilated patients in the ICU), severe (30% of mortality) and have no specific treatment. Impaired epithelial repair ...
Eligibility Criteria
Inclusion
- Ventilated patients with ARDS criteria as defined by Berlin criteria during the first 48 hours of evolution.
Exclusion
- refusal of patient participation, pregnancy, HIV infection, Respiratory insufficiency, Pulmonary fibrosis, cirrhosis (\> Child B score), scleroderma, Alzheimer's disease, Bone marrow transplant, chemotherapy-induced aplasia, immunosuppressive therapy, Corticosteroids (\> 200 mg/day of hydrocortisone or equivalent in the two weeks preceding inclusion), End of life patient or IGS2 greater than 90, brain death, therapeutic limitation.
Key Trial Info
Start Date :
November 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 11 2016
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT01854424
Start Date
November 1 2013
End Date
July 11 2016
Last Update
March 22 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital TENON, département d'anesthésie-réanimation
Paris, France, 75970